ISAR-REACT 2 trial

Introduction

Study characteristics:

• multicenter, randomized, double-blind, placebo-controlled
• 2202 patients

Treatment groups:*

• abciximab 0.25 mg/kg bolus, then 0.125 ug/kg/minute for 12 hours + 70 U/kg heparin
• placebo

* pretreatment of both groups with 600 mg of clopidogrel

Primary endpoint:

• composite
  • death
  • myocardial infarction
  • revascularization within 30 days

Results:

• endpoint reached less often in abciximab group vs placebo (8.9% vs. 11.9%) {25% relative risk reduction}
• relative risk reduction of 29% of insubset of patients with elevated troponin levels
• no risk reduction without elevated troponin
• no significant differences in risk for major bleeding abciximab vs placebo (1.4% and 1.4%)
• risk for minor bleeding (4.2% vs 3.3%)
• need for transfusion (2.5% vs 2.0%)

More general terms

• clinical trial